Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of genetic and non-genetic factors on clinical responses to prochlorperazine in oxycodone-treated cancer patients.

Clinica chimica acta; international journal of clinical chemistry - 15 Feb 2014

Tashiro Masaki, Naito Takafumi, Ohnishi Kazunori, Kagawa Yoshiyuki, Kawakami Junichi

Abstract excerpt

BACKGROUND: The contributions of DRD2 and OPRM1 genetic variants to clinical responses to prochlorperazine remain to be clarified in opioid-treated patients. We evaluated the clinical responses to prochlorperazine based on non-genetic and genetic factors in oxycodone-treated patients. METHODS: Seventy Japanese cancer patients starting oral prochlorperazine together with oxycodone were enrolled. Predose plasma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Genetic Variation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multivariate Analysis

Share to Nausea

Share to Neoplasms

Share to Prolactin

Share to Receptors, Dopamine D2

Share to Treatment Outcome

Source

Identifiers

PMID: 24360851
DOI: 10.1016/j.cca.2013.12.011

Genes

DRD2
OPRM1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of genetic and non-genetic factors on clinical responses to prochlorperazine in oxycodone-treated cancer patients.PMID 24360851Read ↗

Influence of genetic variants of opioid-related genes on opioid-induced adverse effects in patients with lung cancer: A STROBE-compliant observational study.Semantic proximity Read ↗

OPRM1 c.118A>G Polymorphism and Duration of Morphine Treatment Associated with Morphine Doses and Quality-of-Life in Palliative Cancer Pain Settings.Semantic proximity Read ↗

Association of the OPRM1 variant rs1799971 (A118G) and clinical manifestations in tramadol poisoned patients: a cross-sectional study.Semantic proximity Read ↗

Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients.Semantic proximity Read ↗

Haplotype-Based Association and In Silico Studies of OPRM1 Gene Variants with Susceptibility to Opioid Dependence Among Addicted Iranians Undergoing Methadone Treatment.Semantic proximity Read ↗

Oxycodone/naloxone versus Tapentadol in real-world chronic non-cancer pain management: a prospective controlled and pharmacogenetic studySemantic proximity Read ↗

Sex Differences in Opioid Response Linked to OPRM1 and COMT genes DNA Methylation/Genotypes Changes in Patients with Chronic PainSemantic proximity Read ↗

Naltrexone Use in Treating Hypersexuality Induced by Dopamine Replacement Therapy: Impact of OPRM1 A/G Polymorphism on Its Effectiveness.Semantic proximity Read ↗

OPRM1 influence on and effectiveness of an individualized treatment plan for prescription opioid use disorder patients.Semantic proximity Read ↗

[Genetic polymorphism affects the clinical effects of opioids after surgery].Semantic proximity Read ↗

Study on the association between adverse drug reactions to opioids and gene polymorphisms: a case-case-control study.Semantic proximity Read ↗

Comparison of the Effects of OPRM1 A118G Polymorphism Using Different Opioids: A Prospective Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.